Huntsman Cancer Institute

Phase	Trial	Trial Status	Site Status	Drug [asc]	NCT#
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
1/2	Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors	Terminated	Closed	CB-839 + Talazoparib	NCT03875313
2	Study of Imatinib and Pegylated Interferon-a 2B in Imatinib-naïve Gastrointestinal Stromal Tumor (GIST) Patients	Terminated	Closed	Imatinib + Pegylated Interferon-a 2B	NCT00585221
2	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Ongoing, but not recruiting	Closed	MEK162 + BYL719	NCT01449058
1/2	Phase I/II Study of PDR001 in Patients With Advanced Malignancies	Active, not recruiting	Closed	PDR001	NCT02404441
1	A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT02571036
2	A Study of R1507 in Patients With Recurrent or Refractory Sarcoma	Does not allow GIST	Closed	R1507	NCT00642941
3	Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy	No longer avalable	Closed	Regorafenib (BAY 73-4506)	NCT01646593